Literature DB >> 16841299

Transgenic expression of a CD83-immunoglobulin fusion protein impairs the development of immune-competent CD4-positive T cells.

Katja Lüthje1, Sven O Cramer, Svenja Ehrlich, Alexandra Veit, Christiane Steeg, Bernhard Fleischer, Arne von Bonin, Minka Breloer.   

Abstract

The murine transmembrane glycoprotein CD83 is an important regulator for both thymic T cell maturation and peripheral T cell response. CD83 deficiency leads to a block in the thymic maturation of CD4-positive T cells, and interference with peripheral CD83/CD83 ligand interaction by addition of soluble CD83 suppresses immune responses in vivo and in vitro. Here we report the generation of a mouse transgenic for a fusion protein consisting of the extracellular domain of murine CD83 fused to the constant part of human IgG1 heavy chain. Thymic selection of CD4-positive T cells was unchanged in CD83Ig transgenic and in CD83Ig/OT-2 double-transgenic mice. However, thymic and peripheral CD4-positive T cells derived from CD83Ig/OT-2 transgenic mice displayed a reduced cytokine response to antigenic stimulation in vitro, whereas CD83Ig/OT-1-derived CD8-positive T cells showed normal cytokine secretion. The T cell defect was relevant in vivo, since a sub-lethal infection with Trypanosoma cruzi led to an increased parasitemia and reduced survival rate of CD83Ig transgenic mice compared to wild-type C57BL/6 mice. In contrast, in vivo application of recombinant CD83Ig did not result in an increase in parasitemia. Taken together our data suggest that thymic selection in the presence of CD83Ig leads to an intrinsic T cell defect of CD4-positive T cells resembling the phenotype described for CD4-positive T cells derived from CD83-deficient mouse strains.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16841299     DOI: 10.1002/eji.200636068

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

Review 1.  Dendritic cell CD83: a therapeutic target or innocent bystander?

Authors:  Charlene M Prazma; Thomas F Tedder
Journal:  Immunol Lett       Date:  2007-10-29       Impact factor: 3.685

2.  Podoplanin-Fc reduces lymphatic vessel formation in vitro and in vivo and causes disseminated intravascular coagulation when transgenically expressed in the skin.

Authors:  Leah N Cueni; Lu Chen; Hui Zhang; Daniela Marino; Reto Huggenberger; Annamari Alitalo; Roberta Bianchi; Michael Detmar
Journal:  Blood       Date:  2010-08-17       Impact factor: 22.113

3.  Cytomegalovirus mediates expansion of IL-15-responsive innate-memory cells with SIV killing function.

Authors:  Gema Méndez-Lagares; Ning Chin; W L William Chang; Jaewon Lee; Míriam Rosás-Umbert; Hung T Kieu; David Merriam; Wenze Lu; Sungjin Kim; Lourdes Adamson; Christian Brander; Paul A Luciw; Peter A Barry; Dennis J Hartigan-O'Connor
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 14.808

4.  The CD83 reporter mouse elucidates the activity of the CD83 promoter in B, T, and dendritic cell populations in vivo.

Authors:  Matthias Lechmann; Naomi Shuman; Andrew Wakeham; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-13       Impact factor: 11.205

5.  Targeting CD83 for the treatment of graft-versus-host disease.

Authors:  Xiongfei Wang; Ming Q Wei; Xiaosong Liu
Journal:  Exp Ther Med       Date:  2013-04-02       Impact factor: 2.447

6.  CD83 modulates B cell function in vitro: increased IL-10 and reduced Ig secretion by CD83Tg B cells.

Authors:  Birte Kretschmer; Katja Lüthje; Andreas H Guse; Svenja Ehrlich; Friedrich Koch-Nolte; Friedrich Haag; Bernhard Fleischer; Minka Breloer
Journal:  PLoS One       Date:  2007-08-15       Impact factor: 3.240

7.  Thymic CD4 T cell selection requires attenuation of March8-mediated MHCII turnover in cortical epithelial cells through CD83.

Authors:  Julia von Rohrscheidt; Elisabetta Petrozziello; Jelena Nedjic; Christine Federle; Lena Krzyzak; Hidde L Ploegh; Satoshi Ishido; Alexander Steinkasserer; Ludger Klein
Journal:  J Exp Med       Date:  2016-08-08       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.